WOBURN, Mass., March 22, 2017 /PRNewswire/ -- Medicinal Genomics (MGC) and Courtagen Life Sciences today announced
According to an ESPN poll released in November 2016, 61% of NFL players believed painkiller use would decrease if the league allowed medical cannabis as an alternative. For recovery and pain control, more players preferred cannabis over painkillers. At a time when 33,000 Americans per year are dying from opioid overdoses, and with NFL players four times more likely than the general population to develop painkiller addictions, the players' feedback should come as no surprise.
With cannabis in the spotlight as both current and former athletes fight for the right to access and use their medicine legally, this panel will take an introspective look at all sides of the matter. The discussion will incorporate cannabis use as it relates to sports from a training, focus, and recovery aspect. Speakers will also explore the use of CBD in terms of helping athletes protect themselves from CTE (Chronic Traumatic Encephalopathy), chronic inflammation, and other debilitating consequences from long-term participation in contact sports.
The "Cannabis as Medicine in Professional Sports" panel will take place on Tuesday, April 11th at 1:50pm featuring:
Joining this noteworthy discussion will be moderator, Jim McAlpine, Founder of the 420 Games and NewWest Summit, and co-owner of Power Plant Fitness, a cannabis-friendly San Francisco gym.
For additional details or to register for CannMed 2017, visit http://www.cannmedevents.com/. Follow on Facebook, Twitter, and Instagram with hashtags #CannMed #CannMed2017.
Editors: Passes are available for accredited media upon request.
About Medicinal Genomics Corporation
Medicinal Genomics Corporation applies state-of-the-art life science technology to cannabis plant genetics, and was the first company to sequence the cannabis genome. Our products, based on Next Generation DNA Sequencing technology, help growers, dispensaries, and safety testing laboratories characterize and understand the quality of medicinal cannabis. Medicinal Genomics is a wholly owned subsidiary of Courtagen Life Sciences, Inc. For more information, please visit http://www.medicinalgenomics.com/
About Courtagen Life Sciences, Inc.
Courtagen Life Sciences, Inc. is a CAP/CLIA certified molecular information company focused on the diagnosis of a range of neurological, endocrine, and functional disorders associated with the central, peripheral, and autonomic nervous systems, including the endocannabinoid receptor system. Courtagen operates a sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business that helps physicians reveal the genotype to phenotype relationships of various diseases, which may be treated with a range of therapies, including pharmaceuticals and medical cannabis. For more information, please visit http://www.courtagen.com/
Contact:Mike CatalanoMedicinal Genomics151642@email4pr.com 877-395-7608
Jennifer Price, firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannmed-2017-conference-to-feature-former-nfl-players-leading-panel-discussion-on-medical-marijuana-use-in-professional-sports-300427674.html
SOURCE Medicinal Genomics and Courtagen Life Sciences
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All